Affinage

LAMP2

Lysosome-associated membrane glycoprotein 2 · UniProt P13473

Length
410 aa
Mass
45.0 kDa
Annotated
2026-06-10
100 papers in source corpus 26 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LAMP2 is a major lysosomal membrane glycoprotein that integrates autophagy, organelle maturation, and membrane trafficking, with isoform-specific cytosolic tails directing distinct cellular roles (PMID:11082038, PMID:9166415). Its luminal Asn-linked oligosaccharides protect the protein from intralysosomal proteolysis, and loss of LAMP-1/LAMP-2 delays delivery of endocytosed material to dense lysosomes (PMID:10521503). The LAMP-2A isoform serves as the receptor for chaperone-mediated autophagy, binding substrate proteins through four positively-charged residues unique to its cytosolic tail, with lysosomal LAMP-2A levels setting CMA rates (PMID:11082038); the COOH-terminal residue of each splice variant's cytosolic tail determines its steady-state partition between lysosomes and the cell surface (PMID:9166415). Beyond CMA, LAMP2 is broadly required for macroautophagy: it is needed to incorporate syntaxin-17 into autophagosomes, a prerequisite for autophagosome–lysosome fusion (PMID:27628032), and its deficiency in vivo prolongs autophagic vacuole half-life and disrupts lysosomal enzyme trafficking, including cathepsin D processing and mannose-6-phosphate receptor recycling (PMID:12221139). LAMP2 also drives phagosome maturation through Rab7/RILP-dependent centripetal transport (PMID:17506821), mediates endosomal/lysosomal cholesterol export via its luminal membrane-proximal domain (PMID:19929948), and stabilizes partner membrane proteins such as the lysosomal peptide transporter TAPL/ABCB9 against degradation (PMID:22641697). The protein's stability and function are further tuned by glycan-dependent interactions, including galectin-9 binding at Asn175 that supports autophagy (PMID:32855403), and by a CREG1–FBXO27 axis controlling its proteasomal turnover (PMID:37658156). Loss of LAMP2 produces tissue-specific autophagy and lysosomal degradation failures in pancreatic acinar cells (PMID:26693174), retinal pigment epithelium (PMID:31699817), vascular smooth muscle (PMID:29463847), and thymic epithelium where it shapes MHC II-restricted CD4 T cell selection (PMID:35535798). At the cell surface LAMP-2 acts in leukocyte adhesion to endothelium (PMID:8660832), as an endocytic receptor on dendritic cells routing antigen into immunogenic exosomes (PMID:28607115), and as the host-cell receptor for Trypanosoma cruzi gp82 (PMID:30609224).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1993 Medium

    Established that LAMP-2 is not a static lysosomal resident but constitutively cycles between the cell surface and lysosomes, framing its dual intracellular/surface biology.

    Evidence HRP-conjugated anti-LAMP-2 Fab' uptake kinetics with Percoll fractionation in rat hepatocytes

    PMID:8276775

    Open questions at the time
    • Molecular machinery controlling recycling not defined
    • Single lab
  2. 1996 Medium

    Showed LAMP-2 reaches lysosomes by a route distinct from LAMP-1, revealing isoform/family-specific trafficking itineraries.

    Evidence Pulse-chase biosynthetic transport kinetics with subcellular fractionation in rat hepatocytes

    PMID:9010755

    Open questions at the time
    • Sorting determinants for the early-endosome route not mapped
  3. 1997 High

    Resolved why LAMP-2 splice variants differ in localization, attributing surface-vs-lysosome partition to the COOH-terminal cytosolic residue rather than machinery saturation.

    Evidence Chimeric LAMP-1/LAMP-2 constructs and C-terminal site-directed mutagenesis with fractionation/microscopy

    PMID:9166415

    Open questions at the time
    • Adaptor proteins reading each tail signal not identified
  4. 1998 High

    Demonstrated that LAMP proteins are sorted at the TGN into a vesicle class distinct from MPR/clathrin carriers, defining a separate biosynthetic export pathway.

    Evidence In vitro TGN budding assay with CMP-sialic acid labeling and brefeldin A/wortmannin dissection

    PMID:9668075

    Open questions at the time
    • Coat/adaptor components of the LAMP vesicle not identified
  5. 1999 High

    Defined a protective function for LAMP-2 luminal glycans and showed LAMP depletion slows endocytic delivery to dense lysosomes without altering lumenal pH.

    Evidence In-cell endoglycosidase H deglycosylation, metabolic labeling, and fractionation/pH assays

    PMID:10521503

    Open questions at the time
    • Identity of the proteases degrading deglycosylated LAMP-2 not established
  6. 2000 High

    Identified LAMP-2A as the CMA receptor and pinpointed four cytosolic-tail basic residues as the substrate-binding determinant, linking receptor abundance to pathway flux.

    Evidence Isoform-specific antibodies, substrate binding assays, and tail mutagenesis correlated with CMA rates in rat liver/fibroblasts

    PMID:11082038

    Open questions at the time
    • Structural basis of substrate recognition not resolved
    • Other CMA components not addressed here
  7. 2002 High

    Showed via knockout mice that LAMP-2 loss disrupts autophagic vacuole turnover, lysosomal enzyme processing, and MPR recycling, placing LAMP-2 at multiple trafficking nodes.

    Evidence Quantitative EM, endocytic tracers, cathepsin D metabolic labeling, and MPR immunofluorescence in LAMP-2 KO hepatocytes

    PMID:12221139

    Open questions at the time
    • Direct molecular interactions driving each defect not dissected
  8. 2007 High

    Placed LAMP-1/LAMP-2 upstream of Rab7 in phagosome maturation, explaining a microbicidal defect through arrested RILP/dynein-mediated centripetal transport.

    Evidence Single and double LAMP knockout MEFs and human siRNA with bacterial killing and Rab7/RILP localization assays

    PMID:17506821

    Open questions at the time
    • How LAMPs promote Rab7 acquisition mechanistically is unknown
    • Functional redundancy between LAMP-1 and LAMP-2
  9. 2011 High

    Assigned a CMA-independent role for the LAMP-2 luminal domain in endosomal/lysosomal cholesterol export.

    Evidence LAMP-1/2 double-KO cells, isoform and luminal-truncation rescue, cholesterol esterification assays, and KO mouse liver cholesterol

    PMID:19929948

    Open questions at the time
    • Direct cholesterol-handling partner of the luminal domain not identified
  10. 2012 High

    Identified LAMP-2B as a stabilizing partner of the lysosomal transporter TAPL/ABCB9, showing LAMP proteins protect membrane partners from intraluminal degradation.

    Evidence Proteomic Co-IP, TMD0 domain mapping, and pulse-chase half-life in LAMP-deficient cells

    PMID:22641697

    Open questions at the time
    • Whether other lysosomal transporters are similarly stabilized unknown
  11. 2016 High

    Established that LAMP-2 is required for syntaxin-17 incorporation into autophagosomes, mechanistically explaining its role in autophagosome–lysosome fusion.

    Evidence LAMP-2/double-KO MEFs, tandem mRFP-GFP-LC3 reporter, and LAMP-2A rescue with STX17/VAMP8 localization

    PMID:27628032

    Open questions at the time
    • How LAMP-2 directs STX17 to autophagosomes (direct vs indirect) not resolved
  12. 2016 Medium

    Provided structural insight into the LAMP β-prism fold and revealed opposite N-domain effects on multimerization for LAMP-1 versus LAMP-2.

    Evidence Crystal structure determination and N-domain truncation immunoprecipitation assembly assays

    PMID:27663661

    Open questions at the time
    • Functional consequence of differential assembly not established
    • Single structural study
  13. 2020 High

    Showed glycan-dependent galectin-9 binding at LAMP2 Asn175 sustains lysosomal autophagy and protects autophagy-active epithelia from ER stress.

    Evidence Co-IP, galectin-9 glycan-binding mutants, LAMP2 Asn175 mutagenesis, autophagy flux, and colitis/pancreatic mouse models

    PMID:32855403

    Open questions at the time
    • Downstream lysosomal events of galectin-9 recruitment not mapped
  14. 2023 Medium

    Defined a CREG1–FBXO27 axis controlling LAMP2 stability, identifying FBXO27 as an E3 ligase targeting LAMP2 for proteasomal degradation.

    Evidence Co-IP, CREG1 gain/loss, LAMP2 overexpression rescue, and diabetic cardiomyopathy mouse models

    PMID:37658156

    Open questions at the time
    • Ubiquitination site(s) on LAMP2 not mapped
    • Single lab
  15. 2019 Medium

    Identified surface LAMP-2 as the host receptor for T. cruzi gp82, extending LAMP-2 surface biology to pathogen entry.

    Evidence Antibody blocking, LAMP-1/2 siRNA, and gp82 Co-IP/binding assays in HeLa cells

    PMID:30609224

    Open questions at the time
    • Receptor-ligand interaction not reconstituted with purified components
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How LAMP-2's distinct molecular activities (CMA receptor, STX17 incorporation, cholesterol export, partner stabilization) are coordinated by isoform/glycan state on a single lysosomal membrane remains unresolved.
  • No unified structural/biochemical model linking the luminal and cytosolic functions
  • Adaptors and direct binding partners for most trafficking roles unidentified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0001618 virus receptor activity 1 GO:0038024 cargo receptor activity 1 GO:0098631 cell adhesion mediator activity 1 GO:0140313 molecular sequestering activity 1
Localization
GO:0005886 plasma membrane 5 GO:0005768 endosome 2 GO:0031410 cytoplasmic vesicle 2
Pathway
R-HSA-9612973 Autophagy 5 R-HSA-5653656 Vesicle-mediated transport 4 R-HSA-168256 Immune System 3 R-HSA-1430728 Metabolism 1
Partners
ABCB9CREG1FBXO27LAMP1LGALS9STX17

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 LAMP2A acts as the receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy (CMA). Four positively-charged amino acids uniquely present in the cytosolic tail of LAMP2A are required for substrate protein binding. LAMP2A levels in the lysosomal membrane directly correlate with CMA rates; other LAMP2 isoforms do not show this correlation and substrate proteins do not bind them. Isoform-specific antibodies, substrate binding assays, site-directed mutagenesis of cytosolic tail, quantitative correlation of LAMP2A levels with CMA rates in rat liver and fibroblasts under physiological and pathological conditions Journal of cell science High 11082038
1997 The steady-state subcellular distribution of LAMP-2 splice variants (LAMP-2A, -2B, -2C) is determined largely by the COOH-terminal amino acid residue of their cytosolic tails. LAMP-2C shows predominantly lysosomal distribution, whereas LAMP-2A and LAMP-2B show higher cell-surface levels due to differences in targeting signal recognition, not saturation of trafficking machinery. Chimeric constructs (avian LAMP-1 lumenal domain fused to alternatively spliced LAMP-2 domains), site-directed mutagenesis of COOH-terminal residue, subcellular distribution analysis by microscopy and fractionation The Journal of cell biology High 9166415
1999 Asparagine-linked oligosaccharides protect LAMP-2 (and LAMP-1) from intracellular proteolytic degradation within lysosomes. Endoglycosidase H-mediated removal of Asn-linked glycans from fully folded LAMP-2 in living cells resulted in its rapid degradation. Depletion of LAMP-1 and LAMP-2 delayed transport of endocytosed material to dense lysosomes but did not measurably affect endosomal/lysosomal pH, osmotic stability, density, or degradation rate of internalized BSA. Endoglycosidase H treatment of living cells (in-cell deglycosylation), metabolic labeling, cell fractionation, pH and osmotic stability assays The Journal of biological chemistry High 10521503
2002 LAMP-2 deficiency in hepatocytes prolongs the half-life of both early and late autophagic vacuoles, impairs trafficking of some lysosomal enzymes (including cathepsin D processing and retention), and causes impaired recycling of the 46-kDa mannose 6-phosphate receptor from endosomes to the Golgi, with the receptor accumulating in autophagic vacuoles and having a shorter half-life. Quantitative electron microscopy of LAMP-2 knockout mouse hepatocytes, endocytic tracer studies, enzyme activity measurements, metabolic labeling with immunoprecipitation of cathepsin D, steady-state protein level analysis by Western blot, immunofluorescence of mannose 6-phosphate receptors Molecular biology of the cell High 12221139
2011 LAMP-2 (through its luminal domain, particularly the membrane-proximal half) plays a critical role in endosomal/lysosomal cholesterol export. LAMP-1/LAMP-2 double-deficient cells show a defect in cholesterol esterification due to impaired export from late endosomes/lysosomes. Overexpression of any LAMP-2 isoform (but not LAMP-1) rescues cholesterol accumulation caused by U18666A or LAMP deficiency. This function is distinct from CMA. LAMP-1/2 double-knockout cell studies, LDL receptor and uptake assays, cholesterol esterification assays, overexpression rescue experiments with LAMP-2 isoforms and luminal domain truncations, liver cholesterol measurements in LAMP-2 KO mice Journal of cellular and molecular medicine High 19929948
2016 LAMP-2 is required for the incorporation of syntaxin-17 (STX17) into autophagosomes; in LAMP-2-deficient cells STX17 is absent from autophagosomes, which prevents autophagosome-lysosome fusion. Complementation with LAMP-2A rescues both STX17 autophagosomal localization and autophagosome-lysosome fusion. VAMP8 expression and localization are unchanged in LAMP-2-deficient cells. LAMP-2 and LAMP-1/2 double-deficient mouse embryonic fibroblasts, tandem fluorescent-tagged LC3 (mRFP-GFP-LC3) fusion assay, LAMP-2A complementation, immunofluorescence for STX17 and VAMP8 Biology open High 27628032
1998 Newly synthesized LAMP-1 and LAMP-2 are sorted at the trans-Golgi network (TGN) into transport vesicles that are distinct from clathrin-coated vesicles containing mannose 6-phosphate receptors and gamma-adaptin. LAMP vesicle generation requires ATP, cytosol, and is temperature-dependent and brefeldin A-sensitive but wortmannin-insensitive, unlike MPR/gamma-adaptin vesicles. In vitro TGN vesicle budding assay with tritiated CMP-sialic acid labeling, Nycodenz gradient fractionation, wortmannin and brefeldin A pharmacological inhibition, in vivo sorting assays The Journal of biological chemistry High 9668075
2007 LAMP-1 and LAMP-2 together are required for phagosome maturation and bacterial killing. LAMP-1/2 double-deficient cells fail to kill engulfed Neisseria gonorrhoeae; maturation is arrested prior to Rab7 acquisition, preventing RILP recruitment and dynein/dynactin-mediated centripetal phagosome displacement. Single LAMP-1 or LAMP-2 deficiency alone does not prevent microbicidal activity. LAMP-1, LAMP-2, and double-knockout mouse embryonic fibroblasts; siRNA knockdown in human epithelial cells; bacterial survival assays; immunofluorescence for Rab7, RILP; microscopy of phagosome positioning Cellular microbiology High 17506821
2016 LAMP-1 and LAMP-2 adopt the same β-prism fold as DC-LAMP in their subdomains. The N-domain of LAMP-1 is necessary for multimeric assembly, whereas the N-domain of LAMP-2 is repressive for multimeric assembly, indicating distinct assembly modes for LAMP-1 and LAMP-2. Crystal structure analysis (β-prism fold determination), N-domain truncation constructs, immunoprecipitation assembly assays Biochemical and biophysical research communications Medium 27663661
2012 LAMP-1 and LAMP-2B are the most abundant interaction partners of the lysosomal polypeptide transporter TAPL (ABCB9). The interaction interface maps to the four-transmembrane N-terminal domain (TMD0) of TAPL. LAMP proteins stabilize TAPL on the limiting lysosomal membrane and prevent its sorting to intraluminal vesicles; in LAMP-deficient cells, TAPL half-life is reduced fivefold due to increased lysosomal degradation. The interaction does not affect TAPL subcellular localization or peptide transport activity. Proteomic pull-down/co-immunoprecipitation, domain mapping with TMD0 truncations, LAMP-deficient cell lines for half-life measurements (pulse-chase), peptide transport assays Journal of cell science High 22641697
1996 LAMP-2 (CD107b) at the cell surface of activated peripheral blood mononuclear cells mediates adhesion to vascular endothelium, possibly through interaction with endothelial selectins. Cell surface expression increases rapidly upon PHA stimulation and is confined primarily to CD56+ and CD3+ cells. Flow cytometry for cell-surface LAMP-2 expression, fluorescence-based adhesion assay with blocking antibodies, pharmacological inhibition (colchicine, cycloheximide) Cellular immunology Medium 8660832
1993 LAMP-2 cycles between lysosomes and the plasma membrane along the endocytic pathway in cultured rat hepatocytes. Surface-bound anti-LAMP-2 Fab'-HRP conjugates are taken up and delivered to lysosomes in a saturable, cycloheximide-insensitive manner, demonstrating constitutive recycling of LAMP-2 between the cell surface and lysosomes. HRP-conjugated Fab' fragments against LAMP-2, cell fractionation on Percoll gradients, kinetic analysis of uptake, cycloheximide treatment Journal of biochemistry Medium 8276775
1996 A significant fraction (~45%) of newly synthesized LAMP-2 is transported from the trans-Golgi to early endosomes and then delivered to dense lysosomes via perinuclear late endosomes, a route distinct from the predominantly intracellular (late-endosome-direct) route taken by LAMP-1. Biosynthetic transport kinetics in rat hepatocytes by pulse-chase with subcellular fractionation, quantitative trafficking assays Journal of biochemistry Medium 9010755
1998 The extent of polylactosamine glycosylation of LAMP-2 is determined by its Golgi residence time, not by glycosyltransferase expression levels. Longer transit time through the Golgi (as found in 1-day vs 3-day MDCK cells) results in greater polylactosamine modification of LAMP-2. Endoglycosidase treatment, nocodazole and 20°C block experiments, glycosyltransferase activity assays, MDCK epithelial polarization model Glycobiology Medium 9675228
2017 LAMP-2 (CD107b) functions as an endocytic receptor on the surface of human monocyte-derived dendritic cells (MoDC). After ligation, LAMP-2 is internalized and traffics transiently to the MHC class II loading compartment. Antigen conjugated to anti-LAMP-2 antibody is diverted away from MHC II surface presentation and instead concentrated in exosomes, which are a uniquely effective source of antigen for T cell proliferation. Antibody ligation and internalization assays, live-cell imaging of trafficking to MHC II compartments, flow cytometry for surface HLA-DR, T cell proliferation assays (direct and transwell), extracellular vesicle isolation and characterization by Western blot Journal of immunology Medium 28607115
2019 LAMP-2 on the host cell surface is the receptor for Trypanosoma cruzi metacyclic trypomastigote surface molecule gp82. Antibody to LAMP-2 (but not LAMP-1) significantly reduced T. cruzi invasion; LAMP-2-depleted cells were more resistant to invasion; and co-immunoprecipitation demonstrated that gp82 binds to LAMP-2 but not LAMP-1. Antibody blocking assays, siRNA-mediated LAMP-1 and LAMP-2 knockdown in HeLa cells, co-immunoprecipitation with protein A/G magnetic beads cross-linked with anti-LAMP-1 or anti-LAMP-2 antibodies, dose-response binding assays with recombinant gp82 Cellular microbiology Medium 30609224
2020 Galectin-9 is enriched in lysosomes of gut epithelial cells and binds predominantly to LAMP2 in an N-glycan-dependent manner, specifically at Asn175 of LAMP2. Loss of galectin-9 N-glycan-binding capability depletes galectin-9 from lysosomes and causes defective autophagy, leading to ER stress in autophagy-active cells (Paneth cells and acinar cells) and subsequent colitis and pancreatic disorders. Co-immunoprecipitation, glycan-binding mutant galectin-9 constructs, LAMP2 Asn175 site-specific mutagenesis, immunofluorescence co-localization, autophagy flux assays, mouse models of colitis and pancreatic disease Nature communications High 32855403
2016 FUT1-mediated α1,2-fucosylation of LAMP-2 (and LAMP-1) regulates lysosomal positioning. FUT1 knockdown causes a shift from peripheral to perinuclear lysosomal distribution and is correlated with increased autophagic flux, decreased mTORC1 activity, and enhanced autophagosome-lysosome fusion. FUT1 knockdown, MALDI-TOF glycan analysis, nanoLC-MS3 glycopeptide analysis, immunofluorescence for LAMP-1/2 localization, mTORC1 activity assays, autophagic flux measurements Cell death & disease Medium 27560716
2022 LAMP2 is required for proper autophagy in cortical thymic epithelial cells (cTECs) and for MHC II antigen processing. Genetic inactivation of Lamp2 in thymic stromal cells specifically impairs CD4 T cell development (positive selection) without misdirecting MHC II-restricted cells to the CD8 lineage. This is mechanistically linked to altered MHC II processing and reduced CD4 TCR repertoire diversity. Thymic stroma-specific Lamp2 knockout mice, flow cytometry of T cell subsets, MHC II processing assays, TCR repertoire sequencing Autophagy Medium 35535798
2023 CREG1 protects LAMP2 from proteasomal degradation by inhibiting FBXO27, an E3 ubiquitin ligase that targets LAMP2 for degradation. LAMP2 overexpression reverses the inhibition of autophagy caused by CREG1 knockdown in palmitate-stimulated cardiomyocytes, placing LAMP2 downstream of the CREG1-FBXO27 axis in the regulation of autophagic flux in the heart. Co-immunoprecipitation, CREG1 overexpression/knockdown, LAMP2 overexpression rescue, Western blot for FBXO27 and LAMP2 levels, diabetic cardiomyopathy mouse models Experimental & molecular medicine Medium 37658156
2015 LAMP-2 deficiency in pancreatic acinar cells leads to impaired autophagic flux (accumulation of autophagosomes, failure of autolysosome formation), which progresses to trypsinogen activation, macrophage-driven inflammation, and acinar cell death. Pancreatitis models show LAMP degradation mediated by cathepsin B cleavage near the boundary between luminal and transmembrane domains. LAMP-2 knockout mice (spontaneous pancreatitis model), mass spectrometry to identify cathepsin B cleavage sites, electron microscopy, trypsinogen activation assays, amylase secretion assays Cellular and molecular gastroenterology and hepatology High 26693174
2015 LAMP-2 deficiency in retinal pigment epithelium (RPE) cells retards phagocytic degradation of photoreceptor outer segments, compromises lysosomal degradation, and increases exocytosis, leading to age-dependent accumulation of basal laminar deposits resembling early AMD pathology. LAMP2 expression declines with age in RPE cells. Lamp2 knockout mice, electron microscopy, fundus autofluorescence imaging, immunofluorescence for APOE/APOA1/clusterin/vitronectin, phagocytosis and lysosomal degradation assays in RPE cells, analysis of AMD patient eyes Proceedings of the National Academy of Sciences of the United States of America High 31699817
2018 LAMP-2 deficiency in vascular smooth muscle cells (VSMC) causes accumulation of autophagic vacuoles (impaired mitophagy), phenotypic switching from contractile (α-SMA+) to synthetic (vimentin+) phenotype, mitochondrial fragmentation, enhanced mitochondrial respiration, and overproduction of ROS. In vivo, LAMP-2-deficient mice develop medial arterial thickening with luminal stenosis due to VSMC proliferation. LAMP-2 KO mice (9–24 months), ultrastructural analysis, immunofluorescence for vimentin/α-SMA, LAMP2 siRNA knockdown in human brain VSMC, mitochondrial respiration assays, ROS measurements Scientific reports Medium 29463847
2020 In ischemic cardiomyocytes, LAMP2 overexpression alleviates autophagic flux blockade by promoting the trafficking of cathepsin B and cathepsin D to lysosomes, thereby preventing lysosomal membrane permeabilization (LMP) and cardiomyocyte death. Adenoviral LAMP2 overexpression in OGD-treated cardiomyocytes, cathepsin trafficking assays, LMP assays, cell viability assays, drug/gene-based autophagic flux modulation Frontiers in cell and developmental biology Medium 32117965
1995 LAMP-1 and LAMP-2 are present in the membranes of specific granules and secretory vesicles in human neutrophils, but are absent from azurophil granules. During phagocytosis, both LAMP proteins become concentrated around ingested particles and appear on the cell surface upon mobilization of secretory organelles. Subcellular fractionation, Western blotting, immunostaining, phagocytosis assays in human neutrophil granulocytes The Biochemical journal Medium 7487911
1996 LAMP-2 is present in platelet dense granule membranes in addition to lysosomal granule membranes. Upon thrombin stimulation, LAMP-2 shows biphasic surface expression: early expression associated with dense granule release and late expression associated with lysosomal granule release. In Hermansky-Pudlak syndrome platelets lacking dense granules, only the late lysosome-associated LAMP-2 surface expression is observed. Immunoblotting of dense granule preparations, flow cytometry of thrombin-stimulated platelets, HPS patient platelets as natural dense-granule-deficient control, immunoelectron microscopy with anti-serotonin antibody to identify dense granules Thrombosis and haemostasis Medium 8743190

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Molecular aspects of medicine 762 16973206
2000 Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 721 10972294
2002 Role of LAMP-2 in lysosome biogenesis and autophagy. Molecular biology of the cell 313 12221139
2000 Unique properties of lamp2a compared to other lamp2 isoforms. Journal of cell science 265 11082038
2009 Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 260 19318653
2009 Impaired autolysosome formation correlates with Lamp-2 depletion: role of apoptosis, autophagy, and necrosis in pancreatitis. Gastroenterology 197 19362087
1999 Asparagine-linked oligosaccharides protect Lamp-1 and Lamp-2 from intracellular proteolysis. The Journal of biological chemistry 165 10521503
2015 Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane. Nature communications 148 26658462
2015 Lysosome associated membrane proteins maintain pancreatic acinar cell homeostasis: LAMP-2 deficient mice develop pancreatitis. Cellular and molecular gastroenterology and hepatology 122 26693174
2005 Unifying nomenclature for the isoforms of the lysosomal membrane protein LAMP-2. Traffic (Copenhagen, Denmark) 117 16190986
2015 Danon disease: a phenotypic expression of LAMP-2 deficiency. Acta neuropathologica 113 25589223
1996 Lysosome-associated membrane proteins h-LAMP1 (CD107a) and h-LAMP2 (CD107b) are activation-dependent cell surface glycoproteins in human peripheral blood mononuclear cells which mediate cell adhesion to vascular endothelium. Cellular immunology 99 8660832
1998 Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. International journal of cancer 98 9426697
2001 Disease model: LAMP-2 enlightens Danon disease. Trends in molecular medicine 97 11427988
2016 LAMP-2 is required for incorporating syntaxin-17 into autophagosomes and for their fusion with lysosomes. Biology open 87 27628032
1994 Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer research 80 7954433
2019 Genetic LAMP2 deficiency accelerates the age-associated formation of basal laminar deposits in the retina. Proceedings of the National Academy of Sciences of the United States of America 75 31699817
1997 Different steady state subcellular distributions of the three splice variants of lysosome-associated membrane protein LAMP-2 are determined largely by the COOH-terminal amino acid residue. The Journal of cell biology 75 9166415
2011 Role for LAMP-2 in endosomal cholesterol transport. Journal of cellular and molecular medicine 74 19929948
1995 The lysosomal membrane glycoproteins Lamp-1 and Lamp-2 are present in mobilizable organelles, but are absent from the azurophil granules of human neutrophils. The Biochemical journal 73 7487911
1998 Sorting of lysosomal membrane glycoproteins lamp-1 and lamp-2 into vesicles distinct from mannose 6-phosphate receptor/gamma-adaptin vesicles at the trans-Golgi network. The Journal of biological chemistry 72 9668075
2015 LAMP-2 deficiency leads to hippocampal dysfunction but normal clearance of neuronal substrates of chaperone-mediated autophagy in a mouse model for Danon disease. Acta neuropathologica communications 66 25637286
2020 Lumenal Galectin-9-Lamp2 interaction regulates lysosome and autophagy to prevent pathogenesis in the intestine and pancreas. Nature communications 60 32855403
2016 Lysosome-associated membrane proteins-1 and -2 (LAMP-1 and LAMP-2) assemble via distinct modes. Biochemical and biophysical research communications 60 27663661
2004 LAMP-1 and LAMP-2, but not LAMP-3, are reliable markers for activation-induced secretion of human mast cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology 60 15351990
2007 Arrested maturation of Neisseria-containing phagosomes in the absence of the lysosome-associated membrane proteins, LAMP-1 and LAMP-2. Cellular microbiology 57 17506821
1995 The family of LAMP-2 proteins arises by alternative splicing from a single gene: characterization of the avian LAMP-2 gene and identification of mammalian homologs of LAMP-2b and LAMP-2c. DNA and cell biology 56 7546292
2020 The Lysosomal Membrane Protein Lamp2 Alleviates Lysosomal Cell Death by Promoting Autophagic Flux in Ischemic Cardiomyocytes. Frontiers in cell and developmental biology 52 32117965
2006 LAMP-2 deficient mice show depressed cardiac contractile function without significant changes in calcium handling. Basic research in cardiology 51 16604439
2016 Fucosylation of LAMP-1 and LAMP-2 by FUT1 correlates with lysosomal positioning and autophagic flux of breast cancer cells. Cell death & disease 50 27560716
2016 Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells. PloS one 46 27627761
2002 Danon's disease (X-linked vacuolar cardiomyopathy and myopathy): a case with a novel Lamp-2 gene mutation. Neuromuscular disorders : NMD 44 12398843
1995 Multiple mRNAs encode the avian lysosomal membrane protein LAMP-2, resulting in alternative transmembrane and cytoplasmic domains. Journal of cell science 44 7657727
2023 TMT-based quantitative proteomics revealed protective efficacy of Icariside II against airway inflammation and remodeling via inhibiting LAMP2, CTSD and CTSS expression in OVA-induced chronic asthma mice. Phytomedicine : international journal of phytotherapy and phytopharmacology 43 37451150
2012 The lysosomal polypeptide transporter TAPL is stabilized by interaction with LAMP-1 and LAMP-2. Journal of cell science 42 22641697
2006 Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease. Muscle & nerve 40 16372318
1986 Lysosomal membrane glycoproteins: properties of LAMP-1 and LAMP-2. Biochemical Society symposium 40 3101702
1998 Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders. Clinical chemistry 39 9761240
1993 The genes of major lysosomal membrane glycoproteins, lamp-1 and lamp-2. 5'-flanking sequence of lamp-2 gene and comparison of exon organization in two genes. The Journal of biological chemistry 38 8517882
2014 Indomethacin suppresses LAMP-2 expression and induces lipophagy and lipoapoptosis in rat enterocytes via the ER stress pathway. Journal of gastroenterology 36 25212253
2016 A novel LAMP2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 34 27497751
2022 LAMP2 regulates autophagy in the thymic epithelium and thymic stroma-dependent CD4 T cell development. Autophagy 33 35535798
2023 The CREG1-FBXO27-LAMP2 axis alleviates diabetic cardiomyopathy by promoting autophagy in cardiomyocytes. Experimental & molecular medicine 32 37658156
2016 miR-487b-5p Regulates Temozolomide Resistance of Lung Cancer Cells Through LAMP2-Medicated Autophagy. DNA and cell biology 32 27097129
2005 Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene. Neuromuscular disorders : NMD 32 15907287
1998 The extent of polylactosamine glycosylation of MDCK LAMP-2 is determined by its Golgi residence time. Glycobiology 32 9675228
1996 The lysosomal granule membrane protein, LAMP-2, is also present in platelet dense granule membranes. Thrombosis and haemostasis 32 8743190
2021 Fatty Acids Inhibit LAMP2-Mediated Autophagy Flux via Activating ER Stress Pathway in Alcohol-Related Liver Disease. Cellular and molecular gastroenterology and hepatology 31 34284164
2017 Surface LAMP-2 Is an Endocytic Receptor That Diverts Antigen Internalized by Human Dendritic Cells into Highly Immunogenic Exosomes. Journal of immunology (Baltimore, Md. : 1950) 31 28607115
2010 LAMP2 microdeletions in patients with Danon disease. Circulation. Cardiovascular genetics 31 20173215
2021 LAMP2 Cardiomyopathy: Consequences of Impaired Autophagy in the Heart. Journal of the American Heart Association 30 34459252
2005 Morphological, clinical and genetic aspects in a family with a novel LAMP-2 gene mutation (Danon disease). Neuromuscular disorders : NMD 30 15792868
2019 Phenotyping an adult zebrafish lamp2 cardiomyopathy model identifies mTOR inhibition as a candidate therapy. Journal of molecular and cellular cardiology 29 31228518
2012 Genetic analysis of the LAMP-2 gene promoter in patients with sporadic Parkinson's disease. Neuroscience letters 29 22867958
2008 Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy. Circulation journal : official journal of the Japanese Circulation Society 29 19057086
2019 MiR-207 inhibits autophagy and promotes apoptosis of cardiomyocytes by directly targeting LAMP2 in type 2 diabetic cardiomyopathy. Biochemical and biophysical research communications 28 31564413
2018 CSF lamp2 concentrations are decreased in female Parkinson's disease patients with LRRK2 mutations. Brain research 28 29456132
2016 Identification of LAMP2 Mutations in Early-Onset Danon Disease With Hypertrophic Cardiomyopathy by Targeted Next-Generation Sequencing. The American journal of cardiology 28 27460667
1996 Biosynthetic transport of a major lysosome-associated membrane glycoprotein 2, lamp-2: a significant fraction of newly synthesized lamp-2 is delivered to lysosomes by way of early endosomes. Journal of biochemistry 28 9010755
1993 Cycling of two endogenous lysosomal membrane proteins, lamp-2 and acid phosphatase, between the cell surface and lysosomes in cultured rat hepatocytes. Journal of biochemistry 28 8276775
2023 Dimethyl fumarate ameliorates parkinsonian pathology by modulating autophagy and apoptosis via Nrf2-TIGAR-LAMP2/Cathepsin D axis. Brain research 26 37315723
2020 Dysregulated FAM215A Stimulates LAMP2 Expression to Confer Drug-Resistant and Malignant in Human Liver Cancer. Cells 26 32295144
2018 Small-Vessel Vasculopathy Due to Aberrant Autophagy in LAMP-2 Deficiency. Scientific reports 26 29463847
2017 LAMP-2 mediates oxidative stress-dependent cell death in Zn2+-treated lung epithelium cells. Biochemical and biophysical research communications 26 28483530
2005 Phenotypic heterogeneity in two unrelated Danon patients associated with the same LAMP-2 gene mutation. Neuropediatrics 25 16217705
1999 Expression patterns of murine lysosome-associated membrane protein 2 (Lamp-2) transcripts during morphogenesis. Differentiation; research in biological diversity 25 10448712
2022 Neocryptotanshinone protects against myocardial ischemia-reperfusion injury by promoting autolysosome degradation of protein aggregates via the ERK1/2-Nrf2-LAMP2 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 24 36586206
2021 Activation of mTORC1 by Free Fatty Acids Suppresses LAMP2 and Autophagy Function via ER Stress in Alcohol-Related Liver Disease. Cells 24 34685712
2019 Host cell protein LAMP-2 is the receptor for Trypanosoma cruzi surface molecule gp82 that mediates invasion. Cellular microbiology 24 30609224
2017 Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation). American journal of medical genetics. Part A 24 28627787
1993 Cell surface expression of lysosome-associated membrane proteins (LAMPs) in scleroderma: relationship of lamp2 to disease duration, anti-Sc170 antibodies, serum interleukin-8, and soluble interleukin-2 receptor levels. Clinical immunology and immunopathology 24 8443983
2016 Early onset of cardiomyopathy and intellectual disability in a girl with Danon disease associated with a de novo novel mutation of the LAMP2 gene. Neuropathology : official journal of the Japanese Society of Neuropathology 23 27145725
2012 Danon disease: a focus on processing of the novel LAMP2 mutation and comments on the beneficial use of peripheral white blood cells in the diagnosis of LAMP2 deficiency. Gene 23 22365987
2016 Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. Clinical proteomics 22 26924951
2015 Lamp-2 deficiency prevents high-fat diet-induced obese diabetes via enhancing energy expenditure. Biochemical and biophysical research communications 22 26271596
2003 Identification of a novel LAMP2 mutation responsible for X-chromosomal dominant Danon disease. Neuropediatrics 22 14598234
2020 TSTA3 facilitates esophageal squamous cell carcinoma progression through regulating fucosylation of LAMP2 and ERBB2. Theranostics 21 33042286
2013 What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis? Current opinion in rheumatology 21 23169102
2022 SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma. Blood advances 20 34979567
2017 Malignant cardiac phenotypic expression of Danon disease (LAMP2 cardiomyopathy). International journal of cardiology 20 28874292
1995 Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. European journal of haematology 20 7672086
1997 The rapidly evolving Pem homeobox gene and Agtr2, Ant2, and Lamp2 are closely linked in the proximal region of the mouse X chromosome. Genomics 19 9344676
2021 Clinical features of Danon disease and insights gained from LAMP-2 deficiency models. Trends in cardiovascular medicine 18 34737089
2020 Atmospheric PM2.5 blocking up autophagic flux in HUVECs via inhibiting Sntaxin-17 and LAMP2. Ecotoxicology and environmental safety 18 33039871
2008 Danon disease with typical early-onset cardiomyopathy in a male: focus on a novel LAMP-2 mutation. Pediatric transplantation 18 18282207
2007 LAMP-2 positive vacuolar myopathy with dilated cardiomyopathy. Internal medicine (Tokyo, Japan) 18 17541230
2017 Lysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells. Oncology letters 17 29399154
2015 Expression of LC3, LAMP2, KEAP1 and NRF2 in Salivary Adenoid Cystic Carcinoma. Pathology oncology research : POR 17 26350055
2013 Mosaic tissue distribution of the tandem duplication of LAMP2 exons 4 and 5 demonstrates the limits of Danon disease cellular and molecular diagnostics. Journal of inherited metabolic disease 17 23716275
1991 The nucleotide sequence of a CpG island demonstrates the presence of the first exon of the gene encoding the human lysosomal membrane protein lamp2 and assigns the gene to Xq24. Genomics 17 2032724
2021 miR221 regulates TGF-β1-induced HSC activation through inhibiting autophagy by directly targeting LAMP2. Molecular medicine reports 16 34498712
2020 Danon Disease-Associated LAMP-2 Deficiency Drives Metabolic Signature Indicative of Mitochondrial Aging and Fibrosis in Cardiac Tissue and hiPSC-Derived Cardiomyocytes. Journal of clinical medicine 16 32751926
2019 Retinal dystrophy associated with Danon disease and pathogenic mechanism through LAMP2-mutated retinal pigment epithelium. European journal of ophthalmology 16 30836785
2012 Danon disease caused by two novel mutations of the LAMP2 gene: implications for two ends of the clinical spectrum. Clinical neuropathology 16 22541782
2018 Characterisation of Lamp2-deficient rats for potential new animal model of Danon disease. Scientific reports 15 29720683
2016 Identification of Two Novel LAMP2 Gene Mutations in Danon Disease. The Canadian journal of cardiology 15 27179547
2013 Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease. Gene 15 24334114
2024 Simvastatin exerts neuroprotective effects post-stroke by ameliorating endoplasmic reticulum stress and regulating autophagy/apoptosis balance through pAMPK/LC3B/ LAMP2 axis. Experimental neurology 14 39214348
2018 Cerebrospinal Fluid Concentration of Key Autophagy Protein Lamp2 Changes Little During Normal Aging. Frontiers in aging neuroscience 14 29867441
2008 Danon disease due to a novel splice mutation in the LAMP2 gene. Muscle & nerve 14 18004770

Missed literature

Know a paper Affinage missed for LAMP2? Flag it for the maintainers and the community.

No submissions yet.